You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 遠大醫藥(00512.HK)放量升超6% 重磅產品釔[90Y]微球注射液獲批
格隆匯 02-15 15:01
格隆匯2月15日丨遠大醫藥(00512.HK)漲超6%,報6.1港元,成交額放大至6037萬港元,總市值216.5億港元。公司旗下產品釔[90Y]微球注射液獲批獲批中國上市,系我國首個結直腸癌肝轉移治療產品落地。安信國際維持遠大醫藥“買入”評級,目標價10.32港元,相當於18x/16x/14x的21-23預測市盈率。公司重磅產品Y90樹脂微球獲批,其他創新產品管線也在正常推進。此外,遠大醫藥傳統業務規模持續增長,預計21至23年也將保持37%/15%/11%的高增速。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account